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A B S T R A C T
Despite its high efﬁcacy in anti-tuberculosis therapy, the oral administration of isoniazid (INH) may lead
to poor patient compliance due to hepatotoxicity events. In this context, the transdermal administration
of INH was evaluated, for the ﬁrst time, since this route avoids hepatic ﬁrst pass effect. INH was applied to
porcine skin in Franz diffusion chambers alone and with 5% menthol, limonene or Transcutol1. Infrared
and DSC analyses were selected for mechanistic studies. The transdermal absorption of INH was
sufﬁcient to ensure a systemic therapeutic effect. Menthol was not able to improve the absorption of INH,
but it increased the drug accumulation in skin compared to the control (1.4-fold). Transcutol1 reduced
permeation ﬂux of INH (2.2-fold) and also increased the amount of drug retained in skin (1.7-fold).
Limonene was the most effective excipient since it increased permeation ﬂux of INH (1.5-fold) and lag
time was greatly shortened (2.8-fold). DSC and FTIR analyses of limonene-treated skin suggest higher
degree of disorder in lipid bilayers. Transdermal delivery of INH was positively correlated with log P of
chemical enhancers. INH can be efﬁciently delivered by skin route and speciﬁc excipients may be selected
depending on intended use.
ã 2015 Elsevier B.V. All rights reserved.
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Although new drugs are being developed to face the challenge
of emerging multidrug-resistant strains of Mycobacterium tuber-
culosis, isoniazid (INH) remains a widely used and effective ﬁrst-
line agent. Acute tuberculosis is mostly treated with a multidrug
therapy approach, including rifampicin or pyrazinamide, but INH
monotherapy is typically used in the treatment of latent
tuberculosis (Boelsterli and Lee, 2014). It has an efﬁcacy of more
than 90% in latent tuberculosis if treatment is completed properly
(Acton, 2012).
Oral therapies have been effective in the treatment of
tuberculosis; however, undesirable side effects leading to treat-
ment interruption have been reported (Gülbay et al., 2006). INH-
induced liver injury ranges from a mild to severe form (Cai et al.,
2012). The risk of severe hepatotoxicity caused by isoniazid occurs
in approximately 1–2% of patients and 20% of patients are
associated with elevated plasma levels of hepatic enzyme activity* Corresponding author.
E-mail address: thiagocaon@gmail.com (T. Caon).
http://dx.doi.org/10.1016/j.ijpharm.2015.08.067
0378-5173/ã 2015 Elsevier B.V. All rights reserved.(Sarich et al., 1999). Histopathological analyses revealed the
occurrence of hepatocellular focal or conﬂuent necrosis, often
with periportal inﬂammatory components and hydropic degener-
ation of hepatocytes (Pessayre et al., 1977). This fact limits the
concomitant administration of other drugs, which are metabolized
by via hepatic, such as those used in antiretroviral therapy.
In this context, various interventions have been taken in order
to reduce drug-induced hepatotoxicity and improve patient
compliance. Hepatoprotective effects of different plant prepara-
tions and other well-known antioxidants have been evaluated in in
vitro and in vivo assays (Hussain et al., 2012; Prabakan et al., 2000;
Yue et al., 2009), but further clinical studies should be carried out
to conﬁrm these beneﬁts. Another well-designed way to solve this
problem would be the selection of an administration route able to
avoid the hepatic ﬁrst-pass metabolism and to ensure that
therapeutic concentrations may be achieved. Taking this into
consideration, particulate drug-delivery systems have been
proposed aiming a pulmonary administration. A major break-
through expected out of these formulations is their capacity to
enter into and act directly on Mycobacterium by a variety of
mechanisms (Kaur and Singh, 2014). The particle size needs to be
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permeability in Mycobacterium can be observed. Despite the
advantage of a signiﬁcant surface area, the pulmonary route
presents the limitation of nonreproducible placement of the drug
at the site of absorption in the alveoli (Cereijido, 1992) and the
duration of action is often short-lived (drug can be quickly
removed from the lung through various clearance mechanisms)
(Byron, 1986). Alternatively, transdermal systems for drug delivery
may be considered, given that they are non-invasive and self-
administered, which improve patient compliance, avoid hepatic
ﬁrst-pass metabolism, and may also provide drug release for long
periods of time (Prausnitz and Langer, 2008). Moreover, cases of
cutaneous tuberculosis have been recently reported (dos Santos
et al., 2014), which makes this route even more interesting for the
INH administration. In this context, the purpose of this study was
to investigate, for the ﬁrst time, the potential of the skin for the
systemic delivery of INH and the impact of different well-known
chemical enhancers (limonene, menthol and Transcutol1) on its
absorption using Franz diffusion cells, a model previously
established in our laboratory (Caon et al., 2010, 2014). Mechanistic
studies were carried out using Fourier transform infrared
spectroscopy (FT-IR) and differential scanning calorimetry (DSC).
Based on these ﬁndings, the use of these excipients may be
targeted to topical or systemic formulations.
2. Materials and methods
2.1. Materials
Isoniazid, L-menthol, limonene and Transcutol1 were pur-
chased from Sigma–Aldrich (St. Louis, MO, USA). Krebs bicarbonate
Ringer (KBR) and PBS buffers were prepared according to
standardized protocols. Acetonitrile was of HPLC grade and all
other chemicals and reagents were of analytical grade and used as
received.
2.2. Methods
2.2.1. Ex vivo skin permeation studies
Once pig skin is anatomically, physiologically and biochemi-
cally similar to human skin, this animal model was selected for
the permeation studies (Simon and Maibach, 2000). Further-
more, the follicular structure of pig skin also resembles that of
humans (Jung and Maibach, 2015), which is particularly relevant
in the context of polar molecules as isoniazid. The full thickness
of pig ear skin (1.00  0.05 mm) was obtained from a local
abattoir immediately after slaughter and was transported in ice-
cold KBR buffer (pH 7.4). Unlike INH, the permeability coefﬁcient
of highly lipophilic compounds may be overestimated when full
thickness skin is used (EPA/US, 1992). Given that the investigated
compound has polar nature, in these situations, the dermal layer
acts signiﬁcant barrier properties, and thus the full thickness skin
was considered for the experiments. The skin was initially
cleaned with tap water and the hair and subcutaneous fat tissue
were removed. The skin was placed in a two-chamber glass Franz
diffusion cell with the stratum corneum toward the donor
compartment. An available diffusion area of 1.77 cm2 was
considered. Before the permeation experiments, the donor and
receptor chambers were ﬁlled with 2 and 10 mL of PBS buffer (pH
7.4), respectively. No solubilizing agents were added in the
receptor chamber because INH presents high aqueous solubility.
The system was kept at 37 C by circulating heated water through
an external water jacket, and the solution in the receptor
chamber was continuously stirred at 800 rpm using Teﬂon1
coated magnetic stirrers. After a 30 min-equilibration period to
maintain the tissue hydration level, the PBS buffer solution wasremoved from donor chamber and the impact of different well-
known absorption enhancers (menthol, limonene and Trans-
cutol1) (Dragicevic and Maibach, 2015) on the INH transport was
evaluated by comparing with those of the controls (500 mg/mL
INH in PBS or in 40/60 ethanol/PBS). Once some of these
enhancers present a more lipophilic nature, a previous solubili-
zation in ethanol was performed (5% enhancer in a 40/
60 ethanol/PBS buffer solution containing INH at 500 mg/mL).
The selection of penetration enhancers was based on not only its
efﬁcacy in enhancing skin permeation but also on its dermal
toxicity. Terpenes are generally considered less toxic and with
low irritation potential compared to surfactants and other
synthetic skin penetration enhancers. Furthermore, menthol
and limonene are included in the list of Generally Recognized As
Safe (GRAS) agents issued by US FDA (Sapra et al., 2008).
Transcutol1 is listed in the FDA Inactive Ingredient Database for
transdermal applications given that it has been considered a
nonirritant compound to skin even after prolonged and repeated
contact (Smith and Maibach, 2005; Sullivan et al., 2014). At ﬁxed
time intervals (every 1 h, for 6 h), samples (400 mL) were
withdrawn from the receptor chamber, replaced by the same
volume of fresh medium and quantiﬁed by a previously validated
HPLC method (see Section 2.2.2). At the end of the permeation
experiment, samples of the skin were placed in separate pre-
weighed tubes to determine the amount of INH in each tissue
sample collected. INH was extracted from the skin with 3 mL of
acetonitrile, centrifuged (22,000  g; 10 min) and sonicated
(15 min). The extraction method was validated by spiking the
skin with a known amount of INH (concentrations ranging from
1 to 100 mg/mL and recovery values from 98 to 101%). Critical
mass balance was also determined by considering the total
amount of drug in each of the compartments of the experiment
(receptor compartment, that remaining in the donor compart-
ment and that found in the skin layers). The percentages of
recovery found were 101.2, 98.4, 100.9, 97.1 and 95.8 for treat-
ments only with drug, INH coapplied with ethanol, ethanol/
menthol 5%, ethanol/Transcutol1 5% and ethanol/limonene 5%,
respectively. Regarding the permeation parameters, the steady-
state permeation ﬂux (Js) was determined from the linear slope of
the cumulative amount of INH permeated over time. The lag time
represents the time required to achieve the steady-state ﬂux, and
the permeation coefﬁcient (P) was obtained from the relation
between the ﬂux and the initial concentration of INH added to the
donor compartment (P = Js/Cd). Js,P and lag time from different
treatments were compared using a one-way analysis of variance
(ANOVA) followed by a Tukey’s post-hoc test. The target ﬂux to
ensure a therapeutic effect was calculated using the following
Eq. (1) (Gannu et al., 2010)
Target flux ¼ Css  CLt  BW
A
where Css = the INH concentration at therapeutic level (3–5 mg/
mL) (Fahimi et al., 2011); CLt = total body clearance (5.025 mL/min/
kg = 0.084 mL/h/kg; mean value regarding the limits for both rapid
and slow acetylators) (Kergueris et al., 1986); BW = standard
human body weight of 60 kg; and A = surface area of the diffusion
cell (i.e., 1.77 cm2). The calculated target ﬂux value for INH was
8.52–14.19 mg/cm2h (therapeutic window). This result is a rough
calculation to estimate the amount of IZH in the plasma, but the
effect of particular physiological factors and other aspects related
to the formulation should also be evaluated by more sophisticated
pharmacokinetic models, including in vivo experiments. In view
of the fact that an increased dermal perfusion rate contributes
to increase percutaneous permeation of drugs and the in vitro
model is static (Crutcher and Maibach, 1969), in in vivo conditions,
permeation rates are expected to be even larger.
Fig. 1. Permeation proﬁle of INH (500 mg/mL) alone (*), INH coapplied with
ethanol 40% (w/v) (), INH coapplied with ethanol 40% and menthol 5% (w/v) (!),
INH coapplied with ethanol 40% and Transcutol1 5% (w/v) (), and INH coapplied
with ethanol 40% and limonene 5% (w/v) (&) through porcine ear skin. Data are
presented as mean  SD (n = 6).
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Chromatographic conditions were optimized to obtain good
resolution, a narrow peak shape without tailing, adequate
sensitivity, and short analysis time. The concentrations of both
samples and standard solutions (1–100 mg/mL) were assessed by
HPLC using a Shimadzu LC-10A system (Kyoto, Japan), equipped
with an ultraviolet detector, pump (LC-20ADXR), autoinjector
(Jasco AS-2055 Plus), online degasser (DGU-20A3), and column
heater (CTO-20AC). Chromatographic separation was performed at
40 C using a C18 analytical column (250  4.6 mm, 5.0 mm internal
diameter) (Phenomenex1, Torrance, EUA) preceded by a guard
column of the same packing material. The mobile phase consisted
of acetonitrile and 25 mM ammonium acetate (pH 6.8) in a ratio of
95/5 (v/v). The ﬂow rate was set at 1 mL/min and the total sample
acquisition time was 10 min. The detector and the injection volume
were 261 nm and 20 mL, respectively. The quantiﬁcation method
was validated according to ofﬁcial guidelines. Individual R2 values
for each replicate of the calibration curve were higher than 0.999,
suggesting good linearity for the considered range of INH standard
solutions in PBS buffer. Instrumental, intraday and interday
precision values (n = 6) showed relative standard deviation below
5%, indicating an acceptable variability of INH content determina-
tion. Intraday and interday accuracy values ranged from 99.0% to
100.5% and from 98.7% to 101.6%, respectively. The detection and
quantiﬁcation limits were 0.01 and 0.05 mg/mL, respectively.
2.2.3. Mechanistic studies
2.2.3.1. DSC analysis. After the permeation studies, skin samples
were immediately analyzed by differential scanning calorimeter
(DSC-60; Shimadzu, Kyoto, Japan) in order to identify thermal
transition and the effects provided by the different tested treatments
(limonene, menthol and Transcutol1). Approximately 2 mg of skin
samples (epidermis and stratum corneum were removed for the
analyses) were sealed in aluminum hermetic pans and heated from
30 to 200 C at a rate of 10 C/min in a nitrogen atmosphere (gas ﬂow
rate was set at 100 mL/min). Untreated fresh skin samples were used
as control. A decrease in DH and Tmwas interpreted as an indication
of destabilizing effects provided by the different treatments.
2.2.3.2. FTIR spectral analysis of treated and untreated pig skin. After
the permeation studies, the excess of formulation was removed
from the skin surface with PBS buffer and skin samples were cut
into small circular discs. FTIR spectra were recorded in a frequency
range from 600 to 4000 cm1 (PerkinElmer, Waltham, MA), at
room temperature, with the collection of 20 scans at a resolution of
4 cm1. Untreated fresh skin samples were used as control.
Investigations of vibrational bands provided insight information
about the protein and lipid order–disorder caused by the different
treatments.
3. Results
3.1. Ex vivo skin permeation studies
Fig. 1 shows the permeation proﬁles of INH (500 mg/mL) and
INH coapplied with ethanol, ethanol/menthol 5%, ethanol/Trans-
cutol1 5% and ethanol/limonene 5% (w/v) through porcine ear
skin. INH exhibited high skin permeation with the ﬁnal INH
amount (relative to the amount applied) achieving 15% in the
receptor chamber. This resulted in a P value of 9.1 106 cm/s,
which was approximately 8 times lower than the P value of INH
across intestinal cells (P = 72.7  106 cm/s). Although INH pre-
sented lower dermal absorption, when compared to that of
intestinal absorption, advantages in terms of side effect proﬁles
would justify a transdermal administration. Moreover, theadministration of different systems containing INH at 500 mg/
mL through skin resulted in ﬂux values higher than 8.52 mg/cm2h
(except for the treatment with Transcutol1), which could meet the
target ﬂux, indicating that the concentrations may be enough to
elicit the pharmacological effect (Fig. 1 and Table 1). Despite the
Table 1
Permeation parameters of isoniazid alone and combinations of isoniazid and enhancer.
Js (mean  SD) (mg/cm2 h) TL (mean  SD) (h) P (mean  SD) (cm/h)
INH 16.28  3.20(a) 0.81  0.12(a,b) 0.0326  0.0064(a)
INH/EtOH 13.83  3.57(a) 1.05  0.17(a) 0.0277  0.0072(a)
INH/EtOH/menthol 12.68  2.05(a) 0.83  0.15(a,b) 0.0254  0.0041(a)
INH/EtOH/limonene 24.48  2.50(b) 0.29  0.15(c) 0.0490  0.0050(b)
INH/EtOH/Transcutol1 7.37  0.79(c) 0.60  0.18(b) 0.0147  0.0016(c)
One-way ANOVA with post-hoc Tukey test (p < 0.05) were carried out as appropriate (n = 6). Different letters indicate signiﬁcantly statistical differences among treatments.
Each permeability parameter was analyzed separately. Js = ﬂux; TL = lag time; P = permeability coefﬁcient.
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would provide a reduction in its skin partitioning, its low
molecular weight (258 g/mol) may explain its rapid diffusion
(TL< 1 h), probably by interactions with polar components from
skin surface or by using the follicular route (an alternative
transport route usually used for hydrophilic compounds) (Trauer
et al., 2009). The treatment with limonene or Transcutol1
increased drug diffusion (lag time) through skin layers; however,
statistically signiﬁcant differences compared to control (INH
treatment) were observed only for limonene-treated skin (Table 1).
Limonene-treated skin increased drug absorption (p < 0.05)
through skin while Transcutol1-treated skin had an opposite effect
(p < 0.05) (Fig. 1 and Table 1). In light of these results, excipients
able to increase drug absorption could be used in situations where
dose reduction is required as well as transdermal effect, while
those compounds are able to reduce it in situations aiming a
sustained or controlled drug release.
The amount of INH retained in skin (Fig. 2) was inversely
proportional to lipophilicity of used chemical enhancers. Limo-
nene-treated samples, the most lipophilic enhancer (log P = 4.58)
(El-Kattan et al., 2001), displayed a lower amount of retained INH,
when compared to the other tested enhancers (p < 0.0001), and a
similar retention, when compared to the control (p > 0.05). On the
other hand, the treatment with Transcutol1, which present a log P
value of 0.42 (Heng et al., 2014), increased the drug retention
signiﬁcantly (p < 0.0001), suggesting a depot effect.
3.2. DSC analysis
DSC technique is widely used to investigate the effects of
percutaneous penetration enhancers and retardants on the
thermotropic behavior of skin (by comparing both endothermsFig. 2. Skin retention of INH (500 mg/mL) alone (A), INH coapplied with ethanol 40%
(w/v) (B), INH coapplied with ethanol 40% and menthol 5% (w/v) (C), INH coapplied
with ethanol 40% and limonene 5% (w/v) (D) and INH coapplied with ethanol 40%
and Transcutol1 5% (w/v) (E). Data are presented as mean  SD (n = 6). ***p < 0.0001
(ANOVA/Tukey).and exotherms for mean transition temperature (Tm) and their
enthalpies (H)) (Kaushik and Michniak-Kohn, 2010). DSC thermo-
grams of skin treated with the tested enhancers were evaluated by
comparing the endotherms for Tm and their DH (Fig. 3 and Table 2).
The shift in Tm to a lower temperature is interpreted as disruption
of the lipid bilayer, while the reduction in DH suggests ﬂuidization
of lipid bilayers. Limonene-treated skin samples signiﬁcantly
reduced their Tm values and DH, when compared to the other
treatments (p < 0.05), which indicate that this enhancer has a more
signiﬁcant effect on ﬂuidization and disruption of skin lipid
bilayers. Although skin samples treated with Transcutol1 or
menthol have slightly reduced their Tm values, when compared to
the control (untreated skin), these differences were not statisti-
cally signiﬁcant. These ﬁndings suggest that menthol and Trans-
cutol1 did not cause disruption of skin lipid bilayers. However,
both treatments provided certain membrane ﬂuidization (reduc-
tion in DH). Two and three endothermic events had been observed
for ethanol-treated and untreated skin samples, respectively;
while a single endotherm was observed for skin treated with the
different enhancers. These thermal transitions occurring near 65
and 85 C are attributed to increased acyl chain motion of the
stratum corneum (SC) lipids (Golden et al., 1986).
3.3. FTIR analysis
Spectroscopic studies were performed to investigate the effect
of enhancers on the biophysical properties of the stratum corneum
(SC). It has been already demonstrated that porcine skin is very
close to human skin in structural and chemical properties, and it is
considered a very helpful model for transdermal drug diffusion
studies in combination with FTIR (Kong and Bhargava, 2011). The
FTIR spectrum of untreated SC shows various peaks due to
molecular vibrations of lipids (nonpolar) and proteins (polar) in
the SC (Fig. 4). The bands at 2920 and 2850 cm1 are due to the
asymmetric CH2 and symmetric CH2 vibrations of long chain
hydrocarbons of lipids, respectively, and peaks at 2955 and
2870 cm1 are due to the asymmetric and symmetric CH3
vibrations, respectively (Cotte et al., 2004). Signiﬁcant shifts in
these peaks suggest vibration and disorder of the hydrocarbon
chains (Guillard et al., 2009). Conversely, strong bands at 1650 and
1550 cm1 are related to the amide I and amide II stretching
vibrations of SC proteins (Vashisth et al., 2014). The amide I bands
arises from C¼O stretching vibration and the amide II bands from
CN bending vibration. The amide I band, consisting of compo-
nent bands, represents various secondary structures of keratin.
Thus, understanding the physicochemical properties of INH and
the effect of enhancers on polar and nonpolar skin components, it
is possible to purpose some mechanisms to explain the obtained
transport data of INH through skin. Investigations of vibrational
bands may also provide insight information about the lipid order–
disorder caused by different treatments. In this context, the
treatment with menthol and Transcutol1 increased the degree of
order (2850–2955 cm1) in lipid domains while limonene in-
creased the degree of disorder (ﬂuidity of SC increases with lipid
Fig. 3. DSC thermogram of control (untreated skin, —) and skin treated with different enhancers [ethanol (  ), ethanol/menthol ( ), ethanol/Transcutol1 ( )
and ethanol/limonene ( )] after 6 h.
Table 2
Midpoint transition temperature (from main DSC peak) and calorimetric enthalpy
of components from untreated and enhancer-treated skin (n = 3).
Tm (C) DH (J/g)
Control (untreated skin) 85.32  3.36 584.82  15.62
INH 90.72  4.56 605.61  12.53
INH/EtOH 92.95  2.59 522.08  13.99
INH/EtOH/menthol 84.11  4.99 486.83  21.24
INH/EtOH/limonene 68.02  3.94 178.34  11.93
INH/EtOH/Transcutol1 80.59  6.65 379.68  13.87
T. Caon et al. / International Journal of Pharmaceutics 494 (2015) 463–470 467disorder). On the other hand, the treatment with Transcutol1
slightly increased the degree of order in protein domains (1550–
1650 cm1), while menthol and limonene had opposite effects.
Therefore, it is important to note that Transcutol1 increased the
degree of order of both polar and nonpolar domains. Overall,
limonene-treated skin samples provided a higher degree of
disorder, which is supported by reduction in IR peaks. Although
a slight increase in intensity of IR peaks at 3078 and 3278 cm1
(amide of proteins) was observed for skin samples treated with
limonene, this signal was broad, suggesting a higher degree of
protein disorder. The peak at 1740 cm1 is likely from exogenous
lipid secreted by glands such as the sebaceous glands and remains
in fresh samples (Kong and Bhargava, 2011). This peak was more
remarkable for untreated skin samples and Transcutol1-treated
skin samples (they could retain these exogenous lipids). FI-TR
spectra of skin samples treated with menthol were similar to those
already reported (Fujii et al., 2003). The peak close to 1000 cm1 is
a menthol-originating peak.
4. Discussion
Although INH has shown a lower skin permeation than that of
intestinal absorption, the possibility to avoid hepatotoxicity and
other systemic side effects would justify its transdermal adminis-
tration. Furthermore, therapeutic concentrations can be easily
achieved. In situations where excipients reduce the drugabsorption, higher absorption area may be considered. The high
hydrophilicity of drug explains its lower partitioning into the skin,
given that the skin has a more lipophilic nature. In view of their
physicochemical properties and rapid diffusion through skin
(TL > 1 h), a follicular transport is preferably used for INH. For
the caffeine, another hydrophilic permeant, which present a log P
close to that of INH, was found that more than 50% of this drug is
transported by the follicular route in both in vitro and in vivo
models (Trauer et al., 2009). For that reason, it is desirable that
excipients affect this transport route in order to increase the drug
absorption or extract lipids from SC, reducing the barrier
properties of skin. If excipients act as absorption retardants, the
use in transdermal formulations is limited, but they could be
targeted to topical systems, which may alternatively be used for
the treatment of cutaneous tuberculosis.
Three different well-known absorption enhancers, presenting
different log P values, were selected for this study and their
mechanisms of action on INH transport through skin were
investigated by FTIR and DSC analyses.
The treatment of skin samples with menthol did not affect the
drug permeation parameters (J, P and lag time), but increased the
amount of INH retained in the skin. This excipient provided lower
thermal stress in skin rather than the other tested compounds (see
DSC analysis), and FTIR peaks suggested an increased order degree
of skin layers, especially for nonpolar domains. Moghadam et al.
(2013) suggested that this increased order after menthol treatment
is most likely due to the lessened electronegativity of its hydroxyl
group, making it difﬁcult to interact with ceramide head groups in
the SC bilayer (Moghadam et al., 2013). It has been hypothesized
that terpenes exert their permeation enhancement effects by
competitive hydrogen bonding, i.e., breaking hydrogen bonds
between the head group of ceramides in SC lipids and creating new
bonds with their available moieties. Based on the results obtained,
these new polar chemical sites could be available to interact with
INH, justifying its high retention in the skin (higher drug retention
when compared to the control). A concentration-dependent effect
of menthol on drug transport through skin is also reported
(Krishnaiah et al., 2002), suggesting that the used menthol
AB
C
Fig. 4. FTIR spectra of porcine skin treated with ethanol/menthol (A), ethanol/Transcutol1 (B) and ethanol/limonene (C). (—) untreated skin (  ) treated skin.
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suggested that the addition of ethanol to water and 5% menthol
improves drug solubility in the vehicle and decreases the skin
polarity, which is not interesting for INH given its higher afﬁnity for
polar regions (Kobayashi et al., 1994).
Transcutol1 (log P = 0.42) (Heng et al., 2014) reduced the INH
permeation through skin and also increased its skin retention
signiﬁcantly, suggesting a depot effect (it provided higher skin
retention than menthol). This fact has already been reported by
Godwin et al. (2002), who demonstrated that the inclusion of
Transcutol1 in sunscreen formulations was able to increase theaccumulation of the UV absorbers oxybenzone and cinnamate in
skin without a concomitant increase in transdermal permeation
(Godwin et al., 2002). The mechanism behind the increased skin
accumulation of drugs due to the inclusion of Transcutol1 has been
termed an “intracutaneous depot”. It is hypothesized that this
depot effect is created by a swelling of SC intercellular lipids
without alteration of their multiple bilayer structure. These
swollen lipids then would be able to retain drugs to form the
depot. The obtained results of thermal analysis suggested a higher
membrane ﬂuidization after the treatment with Transcutol1. The
end result of this depot formation is an increased skin
T. Caon et al. / International Journal of Pharmaceutics 494 (2015) 463–470 469accumulation of drug with a simultaneous decrease in transdermal
permeation. Although Transcutol1 is a well-known solubilizing
agent (Censi et al., 2012), this fact does not explain these results,
considering that INH is highly soluble.
Limonene provided the highest increase in the permeation ﬂux
or permeation coefﬁcient of INH. Once this compound possesses a
large log P value (4.58) (El-Kattan et al., 2001), this terpene easily
interacts with SC intercellular lipids, facilitating lipid extraction or
phase transition. Thermal analyses conﬁrmed these ﬁndings
considering that reduced DH and lower Tm were observed for
this sample (p < 0.05). FTIR analyses suggested an increased lipid
disorder or SC lipid extraction since the intensity of IR peaks was
reduced, especially those signals related to nonpolar domains.
Similar results were obtained by Krishnaiah et al. (2004) after rat
skin has been treated with ethanolic solution [60% (v/v) ethanol–
water] of limonene [4% (w/w)] (Krishnaiah et al., 2004).
Additionally, the enhancement action may also be attributed to
the improved diffusivity of INH into skin since the lag time for
permeation was greatly shortened, a mechanism already observed
and attributed to this enhancer in another permeation study with
indomethacin, a hydrophilic permeant (Okabe et al., 1994).
Overall, this study pointed out that ex vivo skin permeation of
INH was positively correlated with log P values of different
chemical enhancers. Different from limonene (log P = 4.58), Trans-
cutol1 presented the lowest log P value (0.42) (Heng et al., 2014)
and the lowest skin permeation (J, P). Mechanistic studies (DSC and
FT-IR analyses) suggested that a very high disorder degree in skin is
required so that lipids from SC can be extracted and a novel
alternative route may be used for INH transport. Only limonene
would be able to extract skin lipids given its high log P value and
low Tm. Transcutol1 and menthol were able to provide some
structural changes in skin (identiﬁed by DSC and FT-IR analyses),
but they were not enough to increase the drug transport. Another
possible explanation is that these two excipients could affect polar
routes, competing with INH by speciﬁc regions and limiting its
transport through skin. Based on the ﬁndings of the present study,
limonene would be a more appropriate excipient to be included in
transdermal formulations due to high INH absorption provided by
this enhancer, while Transcutol1 and menthol would be more
appropriate for topical systems.
5. Conclusions
INH is efﬁciently delivered by skin route, and speciﬁc excipients
may be selected depending on intended use (topical or transder-
mal delivery). Transcutol1 reduced signiﬁcantly the skin perme-
ation of INH, probably due to a depot effect and an increase in
degree of order in lipid and protein domains. Menthol did not affect
the permeation parameters of drug and also increased INH
retention in skin. Both menthol and Transcutol1 contributed to
a higher membrane ﬂuidization, which was conﬁrmed by DSC
analyses. Nevertheless, limonene increased the diffusivity and
permeation of INH in skin, probably due to the higher degree of
disorder in lipid layers (observed in DSC and FITR analyses) and its
potential to extract lipids from membrane. Skin permeation of INH
was positively correlated with log P values of tested enhancers.
Limonene would be a more appropriate excipient to be included in
transdermal formulations while menthol and Transcutol1 are
more adequate for topical or controlled delivery systems. Dermal
toxicity proﬁle of the INH should be evaluated in addition to
formulation studies in future investigations.
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